Clinical data | |
---|---|
Trade names | Gavreto |
Other names | BLU-667 |
AHFS/Drugs.com | Monograph |
MedlinePlus | a620057 |
License data |
|
Routes of administration | By mouth |
Drug class | Tyrosine kinase inhibitor[1] |
Legal status | |
Legal status | |
Identifiers | |
| |
Chemical and physical data | |
Formula | C27H32FN9O2 |
Molar mass | 533.612 g·mol−1 |
3D model (JSmol) | |
| |
|
Pralsetinib, sold under the brand name Gavreto, is a medication used to treat non-small cell lung cancer (NSCLC) and thyroid cancer.[1] It is used in advanced cases which are RET fusion-positive.[1] It is taken by mouth.[1]
Common side effects include constipation, high blood pressure, tiredness, muscle pain, low blood cells, liver problems, and low calcium.[1] Other side effects may include pneumonitis, bleeding, tumor lysis syndrome, and poor wound healing.[1] Use in pregnancy may harm the baby.[1] It is a tyrosine kinase inhibitor.[1]
Pralsetinib was approved for medical use in the United States in 2020.[1] In the United States it costs about 20,100 USD per month.[2] It is not approved for use in the United Kingdom as of 2021.[3]
References
edit- ^ a b c d e f g h i j k l m "Gavreto- pralsetinib capsule". DailyMed. 9 September 2020. Archived from the original on 28 November 2020. Retrieved 24 September 2020.
- ^ "Gavreto Prices, Coupons & Patient Assistance Programs". Drugs.com. Retrieved 29 October 2021.
- ^ "Pralsetinib". SPS - Specialist Pharmacy Service. 4 July 2020. Archived from the original on 29 October 2021. Retrieved 29 October 2021.